About Dr. Xie Qing
Dr. Xie Qing (谢青) is one of China's most distinguished hepatologists and infectious disease specialists, and the Director of the Department of Infectious Diseases and Hepatology at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. She holds the title of Chief Physician and Professor and is nationally recognized as a leading authority on viral hepatitis, liver cirrhosis, and autoimmune liver disease.
Over a career spanning more than three decades, Dr. Xie has established herself as one of China's foremost clinical researchers in hepatology, with a particular focus on chronic hepatitis B and C, antiviral therapy optimization, and non-alcoholic fatty liver disease (NAFLD/NASH). Her contributions to China's national hepatitis B and C treatment guidelines have directly shaped the clinical management of these conditions for hundreds of millions of patients across the country.
China has the world's largest burden of chronic hepatitis B, with approximately 80 million carriers — and Dr. Xie is one of the country's most experienced clinicians in managing this disease across its full spectrum, from early chronic infection to cirrhosis and hepatocellular carcinoma surveillance. International patients with chronic liver disease, viral hepatitis, or autoimmune liver conditions consistently identify Dr. Xie as one of China's top hepatologists for both primary treatment and expert second opinions.
Professional Positions and Affiliations
- Director, Department of Infectious Diseases and Hepatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Chairwoman, Hepatology Committee, Chinese Society of Infectious Diseases
- Vice Chairwoman, Chinese Society of Hepatology
- Editorial Board Member: Journal of Hepatology, Hepatology, Alimentary Pharmacology and Therapeutics, Chinese Journal of Hepatology
- Member, European Association for the Study of the Liver (EASL)
- Member, Asian Pacific Association for the Study of the Liver (APASL)
- Member, American Association for the Study of Liver Diseases (AASLD)
- Principal Investigator, multiple national and international multicenter clinical trials in hepatitis B, hepatitis C, and NASH
Specialties and Clinical Expertise
Dr. Xie's clinical practice covers the full spectrum of liver disease, with particular depth in viral hepatitis and its complications. Her approach integrates the latest antiviral therapies with comprehensive liver disease management, including cirrhosis complications and hepatocellular carcinoma surveillance.
- Chronic Hepatitis B (CHB) — treatment eligibility assessment, antiviral therapy selection (tenofovir alafenamide, entecavir, tenofovir disoproxil), functional cure strategies (HBsAg loss), treatment cessation criteria, and long-term monitoring; management of HBeAg-positive and HBeAg-negative disease; special populations (pregnancy, immunosuppression, renal impairment)
- Chronic Hepatitis C (CHC) — direct-acting antiviral (DAA) therapy with pan-genotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir); treatment of difficult populations including cirrhosis, renal failure, and prior treatment failure; SVR assessment and post-cure surveillance
- Non-Alcoholic Fatty Liver Disease (NAFLD/NASH) — metabolic risk factor management, liver biopsy interpretation, fibrosis staging, and emerging pharmacotherapy (resmetirom, semaglutide); lifestyle intervention programs
- Autoimmune Liver Disease — autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and overlap syndromes; immunosuppressive therapy and ursodeoxycholic acid protocols
- Liver Cirrhosis and Portal Hypertension — variceal bleeding prevention and treatment, ascites management, hepatic encephalopathy, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome; TIPS referral coordination
- Hepatocellular Carcinoma (HCC) Surveillance — ultrasound and AFP-based surveillance programs for cirrhotic patients; coordination with interventional radiology and hepatobiliary surgery for HCC management
- Drug-Induced Liver Injury (DILI) — causality assessment, management, and monitoring; herbal and traditional medicine-induced liver injury (a particularly important issue in China)
- Liver Disease in Special Populations — hepatitis B in pregnancy (antiviral prophylaxis to prevent mother-to-child transmission), liver disease in HIV co-infection, and immunosuppression-related hepatitis B reactivation
Academic and Research Contributions
Dr. Xie Qing has published over 230 peer-reviewed papers in leading international hepatology journals, with a particular focus on the natural history and treatment outcomes of chronic hepatitis B in Chinese patients, the optimization of DAA therapy for hepatitis C, and the epidemiology of NAFLD in China. Her landmark research on hepatitis B functional cure — demonstrating that HBsAg loss is achievable in a meaningful proportion of patients with optimized antiviral therapy — has been widely cited and has influenced international hepatitis B treatment guidelines.
She has served as China Principal Investigator for multiple pivotal Phase III trials that led to the regulatory approval of tenofovir alafenamide (TAF), glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir in China, bringing these transformative therapies to Chinese patients. Her work on NAFLD epidemiology in China — demonstrating that NAFLD now affects approximately 30% of Chinese adults — has been widely cited and has contributed to national public health policy.
Dr. Xie chairs the Hepatology Committee of the Chinese Society of Infectious Diseases and has been a lead author on multiple editions of China's national chronic hepatitis B and C management guidelines. She is a regular invited speaker at EASL (European Association for the Study of the Liver), AASLD (The Liver Meeting), and APASL annual congresses, and serves on the editorial boards of Journal of Hepatology and Hepatology — the two most prestigious journals in the field.
Approach to Patient Care
Dr. Xie is known for her thorough, evidence-based approach to complex liver disease cases. She leads a multidisciplinary hepatology team that brings together hepatologists, hepatobiliary surgeons, interventional radiologists, and oncologists to develop comprehensive management plans for patients with cirrhosis, portal hypertension, and HCC. For international patients — many of whom have chronic hepatitis B or C that has been managed differently in their home countries — Dr. Xie takes particular care to review all available laboratory, imaging, and prior treatment data before forming an independent clinical opinion.
Her familiarity with international treatment guidelines (EASL, AASLD, APASL) makes her an ideal consultant for patients transitioning from Western or other Asian healthcare systems, or those seeking access to the latest antiviral therapies and clinical trials not yet available in their home country.
Hospital: Ruijin Hospital Hepatology Department
Ruijin Hospital's Department of Infectious Diseases and Hepatology is a National Key Clinical Specialty with a long history of excellence in viral hepatitis management dating back to the early days of hepatitis B research in China. The department operates:
- A high-volume Hepatitis B and C Clinic managing thousands of patients on antiviral therapy
- A dedicated Liver Cirrhosis and Portal Hypertension Clinic with integrated gastroenterology and interventional radiology support
- An Autoimmune Liver Disease Clinic for AIH, PBC, and PSC
- A NAFLD/Metabolic Liver Disease Clinic with integrated endocrinology and nutrition support
- A Clinical Trials Unit running multiple Phase II-III studies in hepatitis B functional cure, NASH pharmacotherapy, and novel antiviral agents
- A Liver Cancer Surveillance Program with standardized ultrasound and biomarker monitoring for cirrhotic patients
Why International Patients Choose Dr. Xie Qing
- China's leading hepatitis B specialist — Chairwoman of China's national hepatology committee and national guideline author
- Hepatitis C cure expertise — China PI for pivotal DAA trials; access to all approved pan-genotypic regimens
- EASL, AASLD, and APASL member — aligned with all major international hepatology guidelines
- Journal of Hepatology and Hepatology editorial board — at the forefront of global hepatology research
- Hepatitis B in pregnancy expertise — critical for international patients planning pregnancy with chronic HBV
- DILI expertise — particularly relevant for patients who have taken herbal or traditional medicines
- Clinical trial access — functional cure strategies and novel NASH therapies not yet commercially available
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Ruijin Hospital, 197 Ruijin Er Road, Huangpu District, Shanghai
- Appointment Lead Time: 2″3 weeks for new patients; urgent cases expedited through CMCS
- Consultation Format: In-person consultation; remote pre-consultation lab and imaging review available through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Medical Records: CMCS provides full translation of overseas lab results, liver biopsy reports, and treatment history into Chinese prior to consultation
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking hepatology care with Dr. Xie Qing at Ruijin Hospital. Our services include:
- Priority appointment booking and scheduling coordination
- Medical record, laboratory result, and liver biopsy report translation (English ↔ Chinese)
- Remote pre-consultation lab and imaging review facilitation
- On-site interpretation during consultations and procedures
- Accommodation coordination near Ruijin Hospital
- Insurance liaison and billing support
- Post-treatment follow-up coordination with your home country hepatologist or gastroenterologist
- Clinical trial eligibility assessment for hepatitis B functional cure and NASH studies
📧 Contact us: contract@medicalsh.com
🌐 medicalsh.com
0 commenti